Gilles Salles

Join lymphoma expert Dr. Gilles Salles from Memorial Sloan Kettering as he discusses the recent FDA approval of Epcoritamab for relapsed follicular lymphoma. He reveals the promising EPCOR FL1 trial results, showcasing a striking progression-free survival benefit. Dr. Salles dives into the bispecific nature of Epcoritamab, how it targets CD20 and CD3, and shares insights on side effects like cytokine release syndrome. He also discusses the implications of minimal residual disease testing and where Epcoritamab fits into future treatment strategies.